ID   AT8B1_HUMAN             Reviewed;        1251 AA.
AC   O43520; Q9BTP8;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 3.
DT   12-APR-2017, entry version 174.
DE   RecName: Full=Phospholipid-transporting ATPase IC;
DE            EC=3.6.3.1;
DE   AltName: Full=ATPase class I type 8B member 1;
DE   AltName: Full=Familial intrahepatic cholestasis type 1;
DE   AltName: Full=P4-ATPase flippase complex alpha subunit ATP8B1;
GN   Name=ATP8B1; Synonyms=ATPIC, FIC1, PFIC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANTS PFIC1 SER-288; VAL-308;
RP   645-ILE--ILE-699 DEL AND ARG-892, VARIANTS BRIC1 THR-661 AND
RP   795-GLY--ARG-797 DEL, AND VARIANT THR-1152.
RC   TISSUE=Intestine, and Liver;
RX   PubMed=9500542; DOI=10.1038/ng0398-219;
RA   Bull L.N., van Eijk M.J.T., Pawlikowska L., DeYoung J.A., Juijn J.A.,
RA   Liao M., Klomp L.W.J., Lomri N., Berger R., Scharschmidt B.F.,
RA   Knisely A.S., Houwen R.H.J., Freimer N.B.;
RT   "A gene encoding a P-type ATPase mutated in two forms of hereditary
RT   cholestasis.";
RL   Nat. Genet. 18:219-223(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16177791; DOI=10.1038/nature03983;
RA   Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D.,
RA   Taylor T.D., Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Yang X., Abouelleil A., Allen N.R., Anderson S.,
RA   Bloom T., Bugalter B., Butler J., Cook A., DeCaprio D., Engels R.,
RA   Garber M., Gnirke A., Hafez N., Hall J.L., Norman C.H., Itoh T.,
RA   Jaffe D.B., Kuroki Y., Lehoczky J., Lui A., Macdonald P., Mauceli E.,
RA   Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C., Noguchi H.,
RA   O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K.,
RA   Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R.,
RA   Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 18.";
RL   Nature 437:551-555(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 388-661.
RC   TISSUE=Colon tumor;
RX   PubMed=9548971;
RA   Halleck M.S., Pradhan D., Blackman C.F., Berkes C., Williamson P.L.,
RA   Schlegel R.A.;
RT   "Multiple members of a third subfamily of P-type ATPases identified by
RT   genomic sequences and ESTs.";
RL   Genome Res. 8:354-361(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 359-1251, AND VARIANT
RP   THR-1152.
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=17948906; DOI=10.1002/hep.21950;
RA   Paulusma C.C., Folmer D.E., Ho-Mok K.S., de Waart D.R., Hilarius P.M.,
RA   Verhoeven A.J., Oude Elferink R.P.;
RT   "ATP8B1 requires an accessory protein for endoplasmic reticulum exit
RT   and plasma membrane lipid flippase activity.";
RL   Hepatology 47:268-278(2008).
RN   [6]
RP   FUNCTION.
RX   PubMed=20510206; DOI=10.1016/j.bcp.2010.05.017;
RA   Munoz-Martinez F., Torres C., Castanys S., Gamarro F.;
RT   "CDC50A plays a key role in the uptake of the anticancer drug
RT   perifosine in human carcinoma cells.";
RL   Biochem. Pharmacol. 80:793-800(2010).
RN   [7]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=20512993; DOI=10.1002/hep.23586;
RA   Verhulst P.M., van der Velden L.M., Oorschot V., van Faassen E.E.,
RA   Klumperman J., Houwen R.H., Pomorski T.G., Holthuis J.C., Klomp L.W.;
RT   "A flippase-independent function of ATP8B1, the protein affected in
RT   familial intrahepatic cholestasis type 1, is required for apical
RT   protein expression and microvillus formation in polarized epithelial
RT   cells.";
RL   Hepatology 51:2049-2060(2010).
RN   [8]
RP   INTERACTION WITH TMEM30A AND TMEM30B, AND SUBCELLULAR LOCATION.
RX   PubMed=20947505; DOI=10.1074/jbc.M110.139006;
RA   van der Velden L.M., Wichers C.G., van Breevoort A.E., Coleman J.A.,
RA   Molday R.S., Berger R., Klomp L.W., van de Graaf S.F.;
RT   "Heteromeric interactions required for abundance and subcellular
RT   localization of human CDC50 proteins and class 1 P4-ATPases.";
RL   J. Biol. Chem. 285:40088-40096(2010).
RN   [9]
RP   INTERACTION WITH TMEM30A AND TMEM30B, AND SUBCELLULAR LOCATION.
RX   PubMed=20961850; DOI=10.1074/jbc.M110.139543;
RA   Bryde S., Hennrich H., Verhulst P.M., Devaux P.F., Lenoir G.,
RA   Holthuis J.C.;
RT   "CDC50 proteins are critical components of the human class-1 P4-ATPase
RT   transport machinery.";
RL   J. Biol. Chem. 285:40562-40572(2010).
RN   [10]
RP   INTERACTION WITH TMEM30A AND TMEM30B, AND SUBCELLULAR LOCATION.
RX   PubMed=21914794; DOI=10.1074/jbc.M111.281006;
RA   Takatsu H., Baba K., Shima T., Umino H., Kato U., Umeda M.,
RA   Nakayama K., Shin H.W.;
RT   "ATP9B, a P4-ATPase (a putative aminophospholipid translocase),
RT   localizes to the trans-Golgi network in a CDC50 protein-independent
RT   manner.";
RL   J. Biol. Chem. 286:38159-38167(2011).
RN   [11]
RP   VARIANT BRIC1 THR-661.
RX   PubMed=9918928; DOI=10.1002/hep.510290214;
RA   Tygstrup N., Steig B.A., Juijn J.A., Bull L.N., Houwen R.H.J.;
RT   "Recurrent familial intrahepatic cholestasis in the Faeroe Islands.
RT   Phenotypic heterogeneity but genetic homogeneity.";
RL   Hepatology 29:506-508(1999).
RN   [12]
RP   VARIANT PFIC1 ASN-554.
RX   PubMed=11093741; DOI=10.1053/jhep.2000.20520;
RA   Klomp L.W.J., Bull L.N., Knisely A.S., van Der Doelen M.A.,
RA   Juijn J.A., Berger R., Forget S., Nielsen I.-M., Eiberg H.,
RA   Houwen R.H.J.;
RT   "A missense mutation in FIC1 is associated with Greenland familial
RT   cholestasis.";
RL   Hepatology 32:1337-1341(2000).
RN   [13]
RP   VARIANTS PFIC1 PRO-127; TYR-403; PRO-412; MET-456; HIS-500; PHE-529
RP   DEL; LEU-535; ASN-554; THR-661; GLY-688; ARG-733; SER-853; ARG-892 AND
RP   ARG-1040, VARIANTS BRIC1 ASN-70; ASP-308; PHE-344; TYR-453; GLY-454;
RP   TRP-600; GLN-600; TRP-628; THR-661; THR-694 AND ARG-892, AND VARIANT
RP   ALA-429.
RX   PubMed=15239083; DOI=10.1002/hep.20285;
RA   Klomp L.W.J., Vargas J.C., van Mil S.W.C., Pawlikowska L.,
RA   Strautnieks S.S., van Eijk M.J.T., Juijn J.A., Pabon-Pena C.,
RA   Smith L.B., DeYoung J.A., Byrne J.A., Gombert J., van der Brugge G.,
RA   Berger R., Jankowska I., Pawlowska J., Villa E., Knisely A.S.,
RA   Thompson R.J., Freimer N.B., Houwen R.H.J., Bull L.N.;
RT   "Characterization of mutations in ATP8B1 associated with hereditary
RT   cholestasis.";
RL   Hepatology 40:27-38(2004).
RN   [14]
RP   VARIANTS ICP1 THR-45 AND GLU-203, AND VARIANT GLN-952.
RX   PubMed=15657619; DOI=10.1038/sj.ejhg.5201355;
RA   Painter J.N., Savander M., Ropponen A., Nupponen N., Riikonen S.,
RA   Ylikorkala O., Lehesjoki A.E., Aittomaki K.;
RT   "Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of
RT   pregnancy.";
RL   Eur. J. Hum. Genet. 13:435-439(2005).
RN   [15]
RP   VARIANT ICP1 CYS-867, AND VARIANTS ASN-70; ILE-305 AND GLN-952.
RX   PubMed=15888793; DOI=10.1136/gut.2004.058115;
RA   Muellenbach R., Bennett A., Tetlow N., Patel N., Hamilton G.,
RA   Cheng F., Chambers J., Howard R., Taylor-Robinson S.D., Williamson C.;
RT   "ATP8B1 mutations in British cases with intrahepatic cholestasis of
RT   pregnancy.";
RL   Gut 54:829-834(2005).
RN   [16]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-886 AND MET-1178.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [17]
RP   CHARACTERIZATION OF VARIANTS PFIC1 VAL-308; ASN-554; THR-661 AND
RP   ARG-1040, CHARACTERIZATION OF VARIANTS BRIC1 ASN-70 AND THR-661,
RP   CHARACTERIZATION OF VARIANT ICP1 CYS-867, AND MUTAGENESIS OF ASP-454.
RX   PubMed=19731236; DOI=10.1002/hep.23158;
RA   Folmer D.E., van der Mark V.A., Ho-Mok K.S., Oude Elferink R.P.,
RA   Paulusma C.C.;
RT   "Differential effects of progressive familial intrahepatic cholestasis
RT   type 1 and benign recurrent intrahepatic cholestasis type 1 mutations
RT   on canalicular localization of ATP8B1.";
RL   Hepatology 50:1597-1605(2009).
RN   [18]
RP   VARIANT PFIC1 THR-209.
RX   PubMed=20038848; DOI=10.1097/MPG.0b013e3181c1b368;
RA   Liu L.Y., Wang X.H., Wang Z.L., Zhu Q.R., Wang J.S.;
RT   "Characterization of ATP8B1 gene mutations and a hot-linked mutation
RT   found in Chinese children with progressive intrahepatic cholestasis
RT   and low GGT.";
RL   J. Pediatr. Gastroenterol. Nutr. 50:179-183(2010).
RN   [19]
RP   VARIANT PFIC1 ILE-1012.
RX   PubMed=23197899; DOI=10.3748/wjg.v18.i44.6504;
RA   Deng B.C., Lv S., Cui W., Zhao R., Lu X., Wu J., Liu P.;
RT   "Novel ATP8B1 mutation in an adult male with progressive familial
RT   intrahepatic cholestasis.";
RL   World J. Gastroenterol. 18:6504-6509(2012).
CC   -!- FUNCTION: Catalytic component of a P4-ATPase flippase complex
CC       which catalyzes the hydrolysis of ATP coupled to the transport of
CC       aminophospholipids from the outer to the inner leaflet of various
CC       membranes and ensures the maintenance of asymmetric distribution
CC       of phospholipids. Phospholipid translocation seems also to be
CC       implicated in vesicle formation and in uptake of lipid signaling
CC       molecules. May play a role in asymmetric distribution of
CC       phospholipids in the canicular membrane. May have a role in
CC       transport of bile acids into the canaliculus, uptake of bile acids
CC       from intestinal contents into intestinal mucosa or both. In
CC       cooperation with ABCB4 may be involved in establishing integrity
CC       of the canalicular membrane thus protecting hepatocytes from bile
CC       salts. Together with TMEM30A is involved in uptake of the
CC       synthetic drug alkylphospholipid perifosine. Involved in the
CC       microvillus formation in polarized epithelial cells; the function
CC       seems to be independent from its flippase activity. Required for
CC       the preservation of cochlear hair cells in the inner ear. May act
CC       as cardiolipin transporter during inflammatory injury.
CC       {ECO:0000269|PubMed:17948906, ECO:0000269|PubMed:20510206,
CC       ECO:0000269|PubMed:20512993}.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + phospholipid(Side 1) = ADP +
CC       phosphate + phospholipid(Side 2).
CC   -!- SUBUNIT: Component of a P4-ATPase flippase complex which consists
CC       of a catalytic alpha subunit and an accessory beta subunit
CC       (Probable). The probable flippase ATP8B1:TMEM30A complex can form
CC       an intermediate phosphoenzyme in vitro. Also interacts with beta
CC       subunit TMEM30B. {ECO:0000269|PubMed:17948906,
CC       ECO:0000269|PubMed:20947505, ECO:0000269|PubMed:20961850,
CC       ECO:0000269|PubMed:21914794, ECO:0000305}.
CC   -!- INTERACTION:
CC       Q9NV96:TMEM30A; NbExp=3; IntAct=EBI-9524729, EBI-2836942;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17948906,
CC       ECO:0000269|PubMed:20947505, ECO:0000269|PubMed:20961850,
CC       ECO:0000269|PubMed:21914794}; Multi-pass membrane protein. Apical
CC       cell membrane {ECO:0000269|PubMed:20512993}. Cell projection,
CC       stereocilium {ECO:0000250|UniProtKB:Q148W0}. Endoplasmic reticulum
CC       {ECO:0000269|PubMed:17948906, ECO:0000269|PubMed:20947505,
CC       ECO:0000269|PubMed:20961850, ECO:0000269|PubMed:21914794}. Golgi
CC       apparatus {ECO:0000269|PubMed:20961850}. Note=Exit from the
CC       endoplasmic reticulum requires the presence of TMEM30A or TMEM30B
CC       (PubMed:20947505). Localizes to apical membranes in epithelial
CC       cells (PubMed:20512993). {ECO:0000269|PubMed:20512993,
CC       ECO:0000269|PubMed:20947505}.
CC   -!- TISSUE SPECIFICITY: Found in most tissues except brain and
CC       skeletal muscle. Most abundant in pancreas and small intestine.
CC   -!- DISEASE: Cholestasis, progressive familial intrahepatic, 1 (PFIC1)
CC       [MIM:211600]: A disorder characterized by early onset of
CC       cholestasis that progresses to hepatic fibrosis, cirrhosis, and
CC       end-stage liver disease before adulthood.
CC       {ECO:0000269|PubMed:11093741, ECO:0000269|PubMed:15239083,
CC       ECO:0000269|PubMed:19731236, ECO:0000269|PubMed:20038848,
CC       ECO:0000269|PubMed:23197899, ECO:0000269|PubMed:9500542}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Cholestasis, benign recurrent intrahepatic, 1 (BRIC1)
CC       [MIM:243300]: A disorder characterized by intermittent episodes of
CC       cholestasis without progression to liver failure. There is initial
CC       elevation of serum bile acids, followed by cholestatic jaundice
CC       which generally spontaneously resolves after periods of weeks to
CC       months. The cholestatic attacks vary in severity and duration.
CC       Patients are asymptomatic between episodes, both clinically and
CC       biochemically. {ECO:0000269|PubMed:15239083,
CC       ECO:0000269|PubMed:19731236, ECO:0000269|PubMed:9500542,
CC       ECO:0000269|PubMed:9918928}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Cholestasis of pregnancy, intrahepatic 1 (ICP1)
CC       [MIM:147480]: A liver disorder of pregnancy. It presents during
CC       the second or, more commonly, the third trimester of pregnancy
CC       with intense pruritus which becomes more severe with advancing
CC       gestation and cholestasis. Cholestasis results from abnormal
CC       biliary transport from the liver into the small intestine. ICP1
CC       causes fetal distress, spontaneous premature delivery and
CC       intrauterine death. ICP1 patients have spontaneous and progressive
CC       disappearance of cholestasis after delivery.
CC       {ECO:0000269|PubMed:15657619, ECO:0000269|PubMed:15888793,
CC       ECO:0000269|PubMed:19731236}. Note=The disease may be caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type)
CC       (TC 3.A.3) family. Type IV subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF038007; AAC63461.1; -; mRNA.
DR   EMBL; AC027097; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF032442; AAC04328.1; -; mRNA.
DR   EMBL; BC003534; AAH03534.1; -; mRNA.
DR   CCDS; CCDS11965.1; -.
DR   RefSeq; NP_005594.1; NM_005603.4.
DR   RefSeq; XP_006722544.1; XM_006722481.3.
DR   RefSeq; XP_011524324.1; XM_011526022.2.
DR   UniGene; Hs.216623; -.
DR   ProteinModelPortal; O43520; -.
DR   BioGrid; 111227; 2.
DR   IntAct; O43520; 2.
DR   STRING; 9606.ENSP00000283684; -.
DR   SwissLipids; SLP:000000342; -.
DR   TCDB; 3.A.3.8.11; the p-type atpase (p-atpase) superfamily.
DR   iPTMnet; O43520; -.
DR   PhosphoSitePlus; O43520; -.
DR   BioMuta; ATP8B1; -.
DR   MaxQB; O43520; -.
DR   PaxDb; O43520; -.
DR   PeptideAtlas; O43520; -.
DR   PRIDE; O43520; -.
DR   Ensembl; ENST00000283684; ENSP00000283684; ENSG00000081923.
DR   GeneID; 5205; -.
DR   KEGG; hsa:5205; -.
DR   UCSC; uc002lgw.5; human.
DR   CTD; 5205; -.
DR   DisGeNET; 5205; -.
DR   GeneCards; ATP8B1; -.
DR   GeneReviews; ATP8B1; -.
DR   HGNC; HGNC:3706; ATP8B1.
DR   HPA; HPA018673; -.
DR   HPA; HPA018674; -.
DR   MalaCards; ATP8B1; -.
DR   MIM; 147480; phenotype.
DR   MIM; 211600; phenotype.
DR   MIM; 243300; phenotype.
DR   MIM; 602397; gene.
DR   neXtProt; NX_O43520; -.
DR   OpenTargets; ENSG00000081923; -.
DR   Orphanet; 99960; Benign recurrent intrahepatic cholestasis type 1.
DR   Orphanet; 69665; Intrahepatic cholestasis of pregnancy.
DR   Orphanet; 79306; Progressive familial intrahepatic cholestasis type 1.
DR   PharmGKB; PA265; -.
DR   eggNOG; ENOG410ITKD; Eukaryota.
DR   eggNOG; ENOG410XPYK; LUCA.
DR   GeneTree; ENSGT00870000136387; -.
DR   HOGENOM; HOG000202528; -.
DR   HOVERGEN; HBG050601; -.
DR   InParanoid; O43520; -.
DR   KO; K01530; -.
DR   OMA; PVQESFF; -.
DR   OrthoDB; EOG091G0139; -.
DR   PhylomeDB; O43520; -.
DR   TreeFam; TF300654; -.
DR   BRENDA; 3.6.3.1; 2681.
DR   Reactome; R-HSA-936837; Ion transport by P-type ATPases.
DR   GeneWiki; ATP8B1; -.
DR   GenomeRNAi; 5205; -.
DR   PRO; PR:O43520; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   Bgee; ENSG00000081923; -.
DR   CleanEx; HS_ATP8B1; -.
DR   ExpressionAtlas; O43520; baseline and differential.
DR   Genevisible; O43520; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031526; C:brush border membrane; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032420; C:stereocilium; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:1901612; F:cardiolipin binding; IEA:Ensembl.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004012; F:phospholipid-translocating ATPase activity; TAS:UniProtKB.
DR   GO; GO:0015721; P:bile acid and bile salt transport; NAS:UniProtKB.
DR   GO; GO:0008206; P:bile acid metabolic process; IEA:Ensembl.
DR   GO; GO:0006855; P:drug transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0007030; P:Golgi organization; IBA:GO_Central.
DR   GO; GO:0060119; P:inner ear receptor cell development; IEA:Ensembl.
DR   GO; GO:0034220; P:ion transmembrane transport; TAS:Reactome.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0045332; P:phospholipid translocation; IDA:UniProtKB.
DR   GO; GO:0032534; P:regulation of microvillus assembly; IMP:UniProtKB.
DR   GO; GO:0007605; P:sensory perception of sound; IEA:UniProtKB-KW.
DR   GO; GO:0021650; P:vestibulocochlear nerve formation; IEA:Ensembl.
DR   Gene3D; 2.70.150.10; -; 1.
DR   Gene3D; 3.40.1110.10; -; 2.
DR   Gene3D; 3.40.50.1000; -; 1.
DR   InterPro; IPR030346; ATP8B1.
DR   InterPro; IPR023299; ATPase_P-typ_cyto_domN.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR008250; ATPase_P-typ_transduc_dom_A.
DR   InterPro; IPR023214; HAD-like_dom.
DR   InterPro; IPR006539; P-type_ATPase_IV.
DR   InterPro; IPR032631; P-type_ATPase_N.
DR   InterPro; IPR001757; P_typ_ATPase.
DR   InterPro; IPR032630; P_typ_ATPase_c.
DR   PANTHER; PTHR24092; PTHR24092; 1.
DR   PANTHER; PTHR24092:SF109; PTHR24092:SF109; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF16212; PhoLip_ATPase_C; 1.
DR   Pfam; PF16209; PhoLip_ATPase_N; 1.
DR   SUPFAM; SSF56784; SSF56784; 3.
DR   SUPFAM; SSF81660; SSF81660; 2.
DR   TIGRFAMs; TIGR01652; ATPase-Plipid; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 1.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cell membrane; Cell projection; Complete proteome;
KW   Disease mutation; Endoplasmic reticulum; Golgi apparatus; Hearing;
KW   Hydrolase; Intrahepatic cholestasis; Lipid transport; Magnesium;
KW   Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN         1   1251       Phospholipid-transporting ATPase IC.
FT                                /FTId=PRO_0000046364.
FT   TOPO_DOM      1    108       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    109    130       Helical. {ECO:0000255}.
FT   TOPO_DOM    131    136       Exoplasmic loop. {ECO:0000255}.
FT   TRANSMEM    137    156       Helical. {ECO:0000255}.
FT   TOPO_DOM    157    340       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    341    362       Helical. {ECO:0000255}.
FT   TOPO_DOM    363    389       Exoplasmic loop. {ECO:0000255}.
FT   TRANSMEM    390    411       Helical. {ECO:0000255}.
FT   TOPO_DOM    412    949       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    950    970       Helical. {ECO:0000255}.
FT   TOPO_DOM    971    982       Exoplasmic loop. {ECO:0000255}.
FT   TRANSMEM    983   1002       Helical. {ECO:0000255}.
FT   TOPO_DOM   1003   1032       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1033   1054       Helical. {ECO:0000255}.
FT   TOPO_DOM   1055   1068       Exoplasmic loop. {ECO:0000255}.
FT   TRANSMEM   1069   1091       Helical. {ECO:0000255}.
FT   TOPO_DOM   1092   1097       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1098   1118       Helical. {ECO:0000255}.
FT   TOPO_DOM   1119   1138       Exoplasmic loop. {ECO:0000255}.
FT   TRANSMEM   1139   1163       Helical. {ECO:0000255}.
FT   TOPO_DOM   1164   1251       Cytoplasmic. {ECO:0000255}.
FT   ACT_SITE    454    454       4-aspartylphosphate intermediate.
FT                                {ECO:0000250}.
FT   METAL       893    893       Magnesium. {ECO:0000250}.
FT   METAL       897    897       Magnesium. {ECO:0000250}.
FT   MOD_RES    1223   1223       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q148W0}.
FT   VARIANT      45     45       N -> T (in ICP1; dbSNP:rs146599962).
FT                                {ECO:0000269|PubMed:15657619}.
FT                                /FTId=VAR_043044.
FT   VARIANT      70     70       D -> N (in BRIC1; compound heterozygote
FT                                with Q-600; uncertain pathological
FT                                significance; may be associated with ICP;
FT                                reduces interaction with TMEM30A;
FT                                dbSNP:rs34719006).
FT                                {ECO:0000269|PubMed:15239083,
FT                                ECO:0000269|PubMed:15888793,
FT                                ECO:0000269|PubMed:19731236}.
FT                                /FTId=VAR_043045.
FT   VARIANT      78     78       H -> Q (in dbSNP:rs3745079).
FT                                /FTId=VAR_029271.
FT   VARIANT     127    127       L -> P (in PFIC1).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043046.
FT   VARIANT     203    203       K -> E (in ICP1; dbSNP:rs56355310).
FT                                {ECO:0000269|PubMed:15657619}.
FT                                /FTId=VAR_043047.
FT   VARIANT     209    209       P -> T (in PFIC1; dbSNP:rs515726138).
FT                                {ECO:0000269|PubMed:20038848}.
FT                                /FTId=VAR_071045.
FT   VARIANT     288    288       L -> S (in PFIC1; dbSNP:rs121909099).
FT                                {ECO:0000269|PubMed:9500542}.
FT                                /FTId=VAR_008809.
FT   VARIANT     305    305       F -> I (in dbSNP:rs150860808).
FT                                {ECO:0000269|PubMed:15888793}.
FT                                /FTId=VAR_043048.
FT   VARIANT     308    308       G -> D (in BRIC1; dbSNP:rs28939685).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043049.
FT   VARIANT     308    308       G -> V (in PFIC1; greatly reduced
FT                                expression due to proteosomal
FT                                degradation; abolishes interaction with
FT                                TMEM30A; dbSNP:rs28939685).
FT                                {ECO:0000269|PubMed:19731236,
FT                                ECO:0000269|PubMed:9500542}.
FT                                /FTId=VAR_008810.
FT   VARIANT     344    344       I -> F (in BRIC1; dbSNP:rs140665115).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043050.
FT   VARIANT     384    384       R -> H (in dbSNP:rs2271260).
FT                                /FTId=VAR_043051.
FT   VARIANT     393    393       I -> V (in dbSNP:rs34315917).
FT                                /FTId=VAR_043052.
FT   VARIANT     403    403       S -> Y (in PFIC1).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043053.
FT   VARIANT     412    412       R -> P (in PFIC1).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043054.
FT   VARIANT     429    429       E -> A (in dbSNP:rs34018205).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043055.
FT   VARIANT     453    453       S -> Y (in BRIC1).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043056.
FT   VARIANT     454    454       D -> G (in BRIC1).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043057.
FT   VARIANT     456    456       T -> M (in PFIC1; dbSNP:rs121909104).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043058.
FT   VARIANT     500    500       Y -> H (in PFIC1; dbSNP:rs147642236).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043059.
FT   VARIANT     529    529       Missing (in PFIC1).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043060.
FT   VARIANT     535    535       H -> L (in PFIC1).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043061.
FT   VARIANT     554    554       D -> N (in PFIC1; greatly reduced
FT                                expression due to proteosomal
FT                                degradation; abolishes interaction with
FT                                TMEM30A; dbSNP:rs121909101).
FT                                {ECO:0000269|PubMed:11093741,
FT                                ECO:0000269|PubMed:15239083,
FT                                ECO:0000269|PubMed:19731236}.
FT                                /FTId=VAR_015423.
FT   VARIANT     577    577       I -> V (in dbSNP:rs3745078).
FT                                /FTId=VAR_029272.
FT   VARIANT     580    580       S -> N (in dbSNP:rs33963153).
FT                                /FTId=VAR_043062.
FT   VARIANT     600    600       R -> Q (in BRIC1; compound heterozygote
FT                                with N-70).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043063.
FT   VARIANT     600    600       R -> W (in BRIC1).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043064.
FT   VARIANT     628    628       R -> W (in BRIC1; dbSNP:rs752045131).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043065.
FT   VARIANT     645    699       Missing (in PFIC1).
FT                                {ECO:0000269|PubMed:9500542}.
FT                                /FTId=VAR_008811.
FT   VARIANT     661    661       I -> T (in BRIC1 and PFIC1; common
FT                                mutation; reduces interaction with
FT                                TMEM30A; dbSNP:rs28939686).
FT                                {ECO:0000269|PubMed:15239083,
FT                                ECO:0000269|PubMed:19731236,
FT                                ECO:0000269|PubMed:9500542,
FT                                ECO:0000269|PubMed:9918928}.
FT                                /FTId=VAR_008812.
FT   VARIANT     674    674       M -> T (in dbSNP:rs35470719).
FT                                /FTId=VAR_043066.
FT   VARIANT     688    688       D -> G (in PFIC1).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043067.
FT   VARIANT     694    694       I -> T (in BRIC1; dbSNP:rs541474497).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043068.
FT   VARIANT     733    733       G -> R (in PFIC1).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043069.
FT   VARIANT     795    797       Missing (in BRIC1).
FT                                {ECO:0000269|PubMed:9500542}.
FT                                /FTId=VAR_008814.
FT   VARIANT     814    814       K -> N (in dbSNP:rs34018300).
FT                                /FTId=VAR_043070.
FT   VARIANT     853    853       F -> S (in PFIC1; dbSNP:rs773092889).
FT                                {ECO:0000269|PubMed:15239083}.
FT                                /FTId=VAR_043071.
FT   VARIANT     867    867       R -> C (in ICP1; reduces interaction with
FT                                TMEM30A; dbSNP:rs121909103).
FT                                {ECO:0000269|PubMed:15888793,
FT                                ECO:0000269|PubMed:19731236}.
FT                                /FTId=VAR_043072.
FT   VARIANT     886    886       A -> V (in a breast cancer sample;
FT                                somatic mutation; dbSNP:rs767398921).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036499.
FT   VARIANT     892    892       G -> R (in PFIC1 and BRIC1;
FT                                dbSNP:rs121909098).
FT                                {ECO:0000269|PubMed:15239083,
FT                                ECO:0000269|PubMed:9500542}.
FT                                /FTId=VAR_008813.
FT   VARIANT     952    952       R -> Q (in dbSNP:rs12968116).
FT                                {ECO:0000269|PubMed:15657619,
FT                                ECO:0000269|PubMed:15888793}.
FT                                /FTId=VAR_029273.
FT   VARIANT    1012   1012       S -> I (in PFIC1).
FT                                {ECO:0000269|PubMed:23197899}.
FT                                /FTId=VAR_071046.
FT   VARIANT    1040   1040       G -> R (in PFIC1; greatly reduces
FT                                interaction with TMEM30A).
FT                                {ECO:0000269|PubMed:15239083,
FT                                ECO:0000269|PubMed:19731236}.
FT                                /FTId=VAR_043073.
FT   VARIANT    1152   1152       A -> T (in dbSNP:rs222581).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:9500542}.
FT                                /FTId=VAR_055045.
FT   VARIANT    1178   1178       I -> M (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036500.
FT   MUTAGEN     454    454       D->A: Greatly reduced expression due to
FT                                proteosomal degradation; abolishes
FT                                interaction with TMEM30A.
FT                                {ECO:0000269|PubMed:19731236}.
FT   CONFLICT   1016   1016       P -> L (in Ref. 4; AAH03534).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1251 AA;  143695 MW;  770FEF3946CB579F CRC64;
     MSTERDSETT FDEDSQPNDE VVPYSDDETE DELDDQGSAV EPEQNRVNRE AEENREPFRK
     ECTWQVKAND RKYHEQPHFM NTKFLCIKES KYANNAIKTY KYNAFTFIPM NLFEQFKRAA
     NLYFLALLIL QAVPQISTLA WYTTLVPLLV VLGVTAIKDL VDDVARHKMD KEINNRTCEV
     IKDGRFKVAK WKEIQVGDVI RLKKNDFVPA DILLLSSSEP NSLCYVETAE LDGETNLKFK
     MSLEITDQYL QREDTLATFD GFIECEEPNN RLDKFTGTLF WRNTSFPLDA DKILLRGCVI
     RNTDFCHGLV IFAGADTKIM KNSGKTRFKR TKIDYLMNYM VYTIFVVLIL LSAGLAIGHA
     YWEAQVGNSS WYLYDGEDDT PSYRGFLIFW GYIIVLNTMV PISLYVSVEV IRLGQSHFIN
     WDLQMYYAEK DTPAKARTTT LNEQLGQIHY IFSDKTGTLT QNIMTFKKCC INGQIYGDHR
     DASQHNHNKI EQVDFSWNTY ADGKLAFYDH YLIEQIQSGK EPEVRQFFFL LAVCHTVMVD
     RTDGQLNYQA ASPDEGALVN AARNFGFAFL ARTQNTITIS ELGTERTYNV LAILDFNSDR
     KRMSIIVRTP EGNIKLYCKG ADTVIYERLH RMNPTKQETQ DALDIFANET LRTLCLCYKE
     IEEKEFTEWN KKFMAASVAS TNRDEALDKV YEEIEKDLIL LGATAIEDKL QDGVPETISK
     LAKADIKIWV LTGDKKETAE NIGFACELLT EDTTICYGED INSLLHARME NQRNRGGVYA
     KFAPPVQESF FPPGGNRALI ITGSWLNEIL LEKKTKRNKI LKLKFPRTEE ERRMRTQSKR
     RLEAKKEQRQ KNFVDLACEC SAVICCRVTP KQKAMVVDLV KRYKKAITLA IGDGANDVNM
     IKTAHIGVGI SGQEGMQAVM SSDYSFAQFR YLQRLLLVHG RWSYIRMCKF LRYFFYKNFA
     FTLVHFWYSF FNGYSAQTAY EDWFITLYNV LYTSLPVLLM GLLDQDVSDK LSLRFPGLYI
     VGQRDLLFNY KRFFVSLLHG VLTSMILFFI PLGAYLQTVG QDGEAPSDYQ SFAVTIASAL
     VITVNFQIGL DTSYWTFVNA FSIFGSIALY FGIMFDFHSA GIHVLFPSAF QFTGTASNAL
     RQPYIWLTII LAVAVCLLPV VAIRFLSMTI WPSESDKIQK HRKRLKAEEQ WQRRQQVFRR
     GVSTRRSAYA FSHQRGYADL ISSGRSIRKK RSPLDAIVAD GTAEYRRTGD S
//
